Primary Care /

Pediatric Psychopharmacology for Primary Care, 4th Edition [Paperback]

Mark A. Riddle, MD and John V. Campo, MD

Format

Price: $94.95

Member Price: $75.95

Quantity

The amount must be greater than 0

Product Information

Description

Completely updated and revised, the fourth edition provides practice-tested, condition-specific treatment recommendations for various childhood mental disorders. Obtain clear evidence-based guidance on dosing, monitoring, and potential adverse reactions of psychotropic medications for treatment of common psychiatric disorders and mental health or behavioral problems in children and adolescents. The book is designed not only for the pediatric primary care clinician but also for specialists such as developmental-behavioral pediatricians, psychiatric nurse practitioners, and allied mental health professionals, among others.

TOPICS INCLUDE

Core pediatric principles and conceptual framework for prescribing psychotropics
Medications for specific diagnoses—ADHD, anxiety, and depression
Food and Drug Administration approved antipsychotics and mood stabilizers and all other medications
Midcourse medication corrections and managing treatment impasses

Details

ISBN-13: 978-1-61002-765-6
Product Code: MA1160
Publication Date: September 12, 2024
Format: Paperback
Pages: 218
Availability: In Stock

About the Authors

Author

Mark A. Riddle, MD

Mark A. Riddle, M.D., Professor of Psychiatry and Pediatrics and Director of the Children’s Interventions Research Program in Psychiatry at the Johns Hopkins University School of Medicine is the editor in chief. The focus of Dr. Riddle’s research, teaching and clinical practice is pediatric psychopharmacology, especially medication side effects. His publications include over 240 research articles, reviews, chapters and edited volumes. He serves as a member of the NICHD-sponsored Data Monitoring Board for the Best Pharmaceuticals for Children Act and as a member of the Institute of Medicine’s Committee on Review of Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. He is the principle investigator of an NIMH-sponsored, multisite study of interventions for children who have gained weight on antipsychotic medication, and the site-PI of a 6-year follow-up study of preschoolers who were treated with medication for ADHD. He was the Director of the Division of Child and Adolescent Psychiatry at Johns Hopkins from 1993-2009 and was the founding chair of the Interventions Review Committee for Disorders Involving Children and Their Families at the National Institute of Mental Health.

Author

John V. Campo, MD

John V. Campo, MD, is the Leonard and Helen R. Stulman Professor of Psychiatry and Behavioral Sciences and Director of the Division of Child and Adolescent Psychiatry at the Johns Hopkins University School of Medicine, as well as Director of Mental Health at the Johns Hopkins Children’s Center and Vice President of Psychiatric Services at Kennedy Krieger Institute. Dr Campo is board-certified in pediatrics, psychiatry, and child and adolescent psychiatry, and completed medical training at the University of Pennsylvania, followed by residencies in pediatrics at the Children’s Hospital of Philadelphia and psychiatry and child and adolescent psychiatry at the Western Psychiatric Institute and Clinic and the University of Pittsburgh Medical Center. In addition to pediatric psychopharmacology, his interests include the integration of mental health services in general medical settings, the relationship between functional somatic symptoms and emotional disorders, and suicide prevention.